Reflecting growing concern over the opioid crisis, Walgreens Boots Alliance (WBA) shareholders voted in favor of a proposal calling for the company to issue a regular report on how it manages the risk of distributing these addictive prescription painkillers, according to preliminary results.

The proposal requires the pharmacy chain to prepare a report by June 30 detailing any changes the company has made to corporate governance since 2012 concerning opioid sales. The report should include specific board oversight of programs pertaining to opioids and whether and how executive compensation has been changed to reflect incentives.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy